To target tumor-associated MUC1 on breast cancer cells, we have generated second-generation CAR MUC1 T cells with two differential costimulatory signals, that is, 41BB and CD28, and determine their immune characteristics and in vitro antitumor activities. This evidence concerns the gene TNFRSF9 and neoplasm.